Replies to post #23711 on Humanigen Inc (fka HGENQ)

[Reggie333]

If HGEN had 1/2 of their retail attention we’d be trading at $40-50 right now.

[cowtown jay]

Don't underestimate leronlimab, friend. The FDA's decision two days ago to allow the resumption of the use of leronlimab for EIND patients was followed up today with FDA guidance for CYDY on adding an open label extension for doctors wanting to use leronlimab in the Phase III trial.

I want HGEN management to be fully aware of the need to pull the trigger if the gun is loaded. If they have told themselves that it would be better to finish enrollment and not to take advantage of the 75% interim review data, I'm not sure they appreciated how close CYDY is to crossing the finish line, assuming they don't get Mesoblasted (rejected for failing to meet primary endpoint in reducing mortality).

[misiu143]

Tscott4- why you saying Leronlimab will not work ...

We know already that it is working ..

M/M study showed Clinically Significant primary endpoint , less objective symptoms ..
And Statistically Significant secondary more objective symptoms NEWS2..

One mistake in this study imo was that they took any patients , if they will concentrate only on patients over 65 and at risk , results should be even more dramatic ..

And they had 65 patients in EIND ..
Those were the most critical not responding to any other treatment ,
yes , few died , but many came off ventilator or ECMO..

Lenzilumab working by affecting GM-CSF
But according to Dr Patterson only 20-30% of patients with covid have elevated GM-CSF.

And in the long haulers GM-CSF is low , but every patient with mild or severe problem has high Rantes

And with Lenzilumab primary endpoint was changed already from mortality to much less important , length of hospitalization ..
And after 50% interim , more patients was added , this mean to me that even this endpoint was difficult to meet ..

No , I personally am not worry about results of Leronlimab S/C study , all indications that Leronlimab will pass , having very difficult mortality as a primary endpoint ..

GLTU

All imo